linjc16/ctgov huggingface dataset:
Cell Therapy as Treatment for Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Official Title
-----------------
Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Biological: Intrathecal autologous bone marrow mononuclear cell transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed cases of any type of Cerebral Palsy age above 6 months. Exclusion Criteria: presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus malignancies bleeding tendencies pneumonia renal failure severe liver dysfunction severe anemia [Hemoglobin < 8] any bone marrow disorder space occupying lesion in brain other acute medical conditions such as respiratory infection and pyrexia.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stem Cell<br>Intrathecal autologous bone marrow mononuclear cell transplantation | Biological: Intrathecal autologous bone marrow mononuclear cell transplantation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in clinical symptoms over a period of 2 years | Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in GMFM score |  | 1 year | 
| Change in Gross Motor Function Measure |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Palsy, autologous bone marrow mononuclear cells, stem cell
Attenuated Inflammatory Response in Laparoscopic Colon Surgery

Study Overview
=================
Brief Summary
-----------------
Pro-inflammatory responses following laparoscopic surgery.

Detailed Description
-----------------
Blood samples from 20 patient with colon cancer collected before and in 3 days following laparoscopic surgery. Analyzed for inflammatory cytokines and corresponding SOCS3 mRNA.

Official Title
-----------------
Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery

Conditions
-----------------
Regulation of Inflammatory Response

Intervention / Treatment
-----------------
* Procedure: Laparoscopic resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Colon cancer stage I-III - Exclusion Criteria:Colon cancer stage IV -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colon cancer patients<br>Laparoscopic resection | Procedure: Laparoscopic resection<br>* Inflammatory response in laparoscopic surgery<br>* Other names: Colon cancer;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory values for laparoscopic resection for colon cancer. | Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer. | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colon cancer
CCC Project - Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.

Official Title
-----------------
Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The overall composite of six performance measures for AF care | Performance measures for AF care including: Proportion of patients received assessment of thromboembolic risk factors Proportion of patients discharged on warfarin or other anticoagulant drug Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge | Duration of hospital stay, an expected average of 1 week |
Treatment of Anterior Ligament Rupture With Internal Brace Repair - A Prospective Randomised Controlled Study.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether anterior cruciate ligament injury in patients wishing to return to sports activities may be treated with repair supplemented with internal brace compared with a standard operation using a patella tendon autograft.

Official Title
-----------------
Treatment of Anterior Ligament Rupture With Internal Brace Repair - A Prospective Randomised Controlled Study Comparing Internal Brace Repair and a Patella Tendon Autograft Reconstruction.

Conditions
-----------------
Ligament; Laxity, Knee, Anterior Cruciate Ligament Injury

Intervention / Treatment
-----------------
* Procedure: Repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anterior cruciate ligament rupture Exclusion Criteria: Current malignant disease Rheumatoid arthritis Other knee ligament instability Obesity BMI >30 Morbus Bechterew

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Repair<br>Anterior cruciate ligament repair with internal brace after anterior ligament rupture. | Procedure: Repair<br>* Anterior ligament repair with internal brace.<br>|
| Active Comparator: Patella tendon graft<br>The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture. | Procedure: Repair<br>* Anterior ligament repair with internal brace.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Laxity | KT-1000 arthrometer | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient reported outcome scores | Koos (Knee injury and Osteoarthritis Outcome Score) | 12 Months | 
| Patient reported outcome scores | IKDC (International Knee Documentation Committee) | 12 Months | 
| Pain measurement | NRS-pain score (Numeric rating scale) (10 worst pain - 0 No pain) | 12 Months |
Biochemical and Genetic Markers in Liver Diseases

Study Overview
=================
Brief Summary
-----------------
Investigation of biochemical and genetic markers in liver disease that might have an influence on the course of the disease

Official Title
-----------------
Biochemical and Genetic Markers in Liver Diseases

Conditions
-----------------
Biochemical and Genetic Markers in Liver Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suffering from liver disease age of 18 years or older agreement to participate in study Exclusion Criteria: younger than 18 years no consent to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Influence of Paternal Age on Assisted Reproduction Outcome

Study Overview
=================
Brief Summary
-----------------
In the recent years, there is an increasing tendency to the parenthood delay in developed countries, and there is not enough information available regarding the influence of the male's age on fertility. If any, the negative impact should be acting at advanced ages. Our aim with this work was to determine the role of paternal age on IUI results embryo quality and IVF outcome. Evenmore, in order to standardize the female factor, good quality oocytes (from fertile oocyte donors) and only first IVF cycles in young women were considered.

Detailed Description
-----------------
A retrospective study has been designed with a total number of 2204 IUI, 1286 IVF cycles and 1412 IVF cycles with donated oocytes from 2000 to 2006. The inclusion criteria will be for IUI: women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index < 27 kg/m2, and absence of polycystic ovarian syndrome and endometriosis. For normal IVF cycles and oocyte donation cycles only first cycles will be analyzed. Cycles will be studied only in couples with absence of severe male factor.

Official Title
-----------------
Influence of Paternal Age on Assisted Reproduction Outcome

Conditions
-----------------
We Will Retrospectively Assess Our Databases in Our Clinic, Instituto Valenciano de Infertilidad in Valencia (Spain), Searching for Assisted Reproduction Procedures, IUI Standard IVF/ICSI Cycles and Ovum Donation IVF/ICSI Cycles, Who Were Referred to Our Unit to Cryopreserve Sperm During the Period, From January 2000 to December 2006

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index < 27 kg/m2. Exclusion Criteria: absence of polycystic ovarian syndrome, hydrosalpinx or endometriosis. Cycles were studied only in couples with absence of severe male factor.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
male age, assisted reproduction, sperm, pregnancy outcome
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.

Official Title
-----------------
A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis

Conditions
-----------------
Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Drug: Daclizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Moderate to severe active ulcerative colitis diagnosed for at least 4 months. Mayo score of 5-10 (inclusive) Not used any investigational therapy for 30 days prior to screening No treatment with monoclonal antibody therapy within 12 weeks of screening No prior treatment with daclizumab

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Daclizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ulcerative Colitis, Inflammatory Bowel Disease, Gastrointestinal, Humanized Monoclonal antibody
Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant

Study Overview
=================
Brief Summary
-----------------
This non-randomized pilot study aims to investigate whether a protein rich nutritional shake (Ensure Enlive) given to patients pre-transplant will decrease skeletal muscle loss (measured by quadriceps ultrasound) and improve nutritional state (measured by Nutritional Risk Index). A nutritional supplement would be a cost-effective solution to treat malnutrition, a known risk factor implicated in poor outcomes for lung transplant recipients.

Official Title
-----------------
A Pilot Study Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant

Conditions
-----------------
Lung Transplant; Complications

Intervention / Treatment
-----------------
* Dietary Supplement: Ensure Enlive


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 18 years or older who are listed for single or double lung transplant Subject provides written informed consent to participate in this study Exclusion Criteria: Subject with history of Galactosemia Subject with history of milk protein allergy Subject with history of soy protein allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Ensure Enlive, Nutritional shake, twice a day
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Nutritional shakes, Ensure Enlive, twice per day orally in patients awaiting lung transplant | Dietary Supplement: Ensure Enlive<br>* Ensure Enlive shake twice a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of nutritional supplementation on skeletal muscle mass as assessed by ultrasound of the quadriceps | To examine the effect of nutritional supplementation on skeletal muscle mass in patients with end stage lung disease who are awaiting lung transplant, measured by ultrasound of the quadriceps. | Pre-transplant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of nutritional supplementation on Nutritional Risk index as assessed by serum albumin level | To examine the effect of nutritional supplementation on Nutritional Risk index, measured by serum albumin level. | Pre-transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pre-hab, nutrition
Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

Study Overview
=================
Brief Summary
-----------------
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Official Title
-----------------
Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Canakinumab 150 MG/ML [Ilaris]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously Age> 18 years Pneumonia diagnosed with Chest X-ray / or Chest CT Exclusion Criteria: Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Canakinumab 150 MG/ML [Ilaris]|COVID-19|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intensive care treatment | percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19 | 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU stay times | ICU stay times | 9 months | 
| % died after 1 month after treatment | percentage of patients who died 1 month after treatment | 9 months | 
| hospitalization | time of hospitalization | 9 months | 
| adverse event | number of adverse event | 9 months |
Optimizing Platelet Isolation (The Cell Study)

Study Overview
=================
Brief Summary
-----------------
The research study is about blood cells (platelets) and their power houses (mitochondria). The investigators want to learn about their behavior in order to ensure that our laboratory procedures are generating optimal results.

Detailed Description
-----------------
The objectives of this study are to assess platelet activation following standard laboratory procedures used in the process of measuring platelet mitochondrial function, and to determine the optimal amount of digitonin needed to permeabilize platelet cell membrane.

Official Title
-----------------
Optimizing Platelet Isolation for Measures of Human Platelet Mitochondrial Respiration (The Cell Study)

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 25-35 All races All ethnicity 18.5 - 30 BMI Exclusion Criteria: smoking Aspirin intake Recreational drug use Alcohol intake more than 3 times per week Self-reported possibility of current pregnancy Known diagnosis of: Pre-diabetes Diabetes High cholesterol High triglycerides Hypertension Anemia Autism spectrum disorder Attention deficit hyperactivity disorder (ADHD) Attention deficit disorder (ADD) Severe asthma Refusal to stop taking nutritional supplements Any other pre-existing medical condition that requires daily medication as determined by the investigators to affect outcome of interest

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet activation from isolated platelets | Whole blood will be collected following an overnight fast, and platelets isolated using standard procedures. Platelet activation markers (e.g., CD62P ) will be measured using flow cytometric analysis. | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet activation measured in whole blood | Whole blood will be collected following an overnight fast. Platelet activation will be measured in whole blood by the expression CD62P | day 1 | 
| Platelet reactivity measured in whole blood | Whole blood will be collected following an overnight fast. Platelet reactivity will be measured in whole blood with adenosine diphosphate (ADP). | day 1 |